Viking Therapeutics (VKTX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
H.C. Wainwright Assumes Viking Therapeutic (VKTX) at Buy, 'An Underappreciated Microcap'
November 10, 2017 7:17 AM ESTH.C. Wainwright assumes coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $7.00.
Analyst Ed Acre takes over coverage of the name and comments "We view Viking as an underappreciated microcap stock with five novel drugs in the... More
